Mode
Text Size
Log in / Sign up

Hyperuricemia acts as an independent risk factor for progression of chronic kidney disease in childrenHigh uric acid levels may drive kidney disease in children

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Recognize hyperuricemia as an independent risk factor for CKD progression and a driver of renal tubulointerstitial injury.

This systematic review explores the pathogenic interplay between hyperuricemia and chronic kidney disease (CKD) in children. The authors synthesize evidence indicating that hyperuricemia serves as an independent risk factor for the onset and progression of CKD, while diminished uric acid excretion from CKD exacerbates hyperuricemia.

The review highlights that elevated serum uric acid induces renal tubulointerstitial injury through three primary mechanisms: oxidative stress, systemic inflammatory cascades, and endothelial dysfunction. These findings suggest that uric acid plays a significant role in the pathophysiology of pediatric renal disease.

Several limitations are noted, including a lack of specific epidemiological evidence for the pediatric population and a lack of evidence-based guidelines tailored to children's unique growth and developmental characteristics. Current management strategies are largely extrapolated from adult studies. The review aims to provide a theoretical foundation for early screening and individualized management of hyperuricemia in children with CKD.

How this fits prior evidence

This review addresses a gap in pediatric-specific management for chronic kidney disease. While prior evidence confirms that SGLT2 inhibitors improve glycemic control and blood pressure in patients with diabetic CKD, and that SGLT2 inhibitors provide the greatest risk reduction for kidney outcomes in type 2 diabetes and CKD, this review focuses on the specific role of hyperuricemia as an independent risk factor for CKD progression in children.

Managing chronic kidney disease in children is complex because their growing bodies have unique needs. New research highlights a specific problem: high levels of uric acid in the blood. This condition, known as hyperuricemia, does not just happen alongside kidney disease. It actually works in a loop with the disease. When kidneys struggle to filter waste, uric acid builds up. This buildup then causes inflammation and stress, which further damages the kidney tissue.

This cycle of damage involves several factors, including oxidative stress and issues with blood vessel function. For children, this means the problem can progress faster than expected. Because many current treatments are based on what works for adults, there is a pressing need for specific guidelines that account for a child's growth and development.

While the evidence for how this specifically affects children is still limited, the link between uric acid and kidney injury is clear. Experts hope this information will lead to earlier screening and better, more personalized care for children facing these kidney challenges.

What this means for you:
High uric acid levels can create a harmful cycle that worsens kidney disease in children.

Common questions

How does high uric acid affect a child's kidneys?

High uric acid levels can cause several types of damage to the kidneys. It leads to oxidative stress, systemic inflammatory cascades, and problems with blood vessel function. These factors together cause injury to the kidney tissue, making it harder for the kidneys to function properly over time.

Why is this a problem for children with kidney disease?

It creates a bidirectional problem. When children have chronic kidney disease, their bodies have a harder time getting rid of uric acid. This buildup then acts as an independent risk factor that can make the kidney disease start sooner or progress more quickly.

Are there specific treatments for children with high uric acid?

Currently, many management strategies for children are based on what works for adults. Because there is limited evidence specifically for the pediatric population, you should speak with a doctor to develop a plan tailored to a child's unique growth and development.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedOct 2026
View Original Abstract ↓
A bidirectional pathogenic interplay exists between pediatric chronic kidney disease (CKD) and hyperuricemia (HUA). Hyperuricemia serves as an independent risk factor for the onset and progression of CKD, while also representing a common complication arising from impaired renal excretory function. Amid the rising global prevalence of pediatric CKD and growing evidence implicating metabolic disturbances in renal injury, the reciprocal pathological mechanisms underlying uric acid–mediated kidney damage have emerged as a critical research focus. Elevated serum uric acid induces renal tubulointerstitial injury through oxidative stress, systemic inflammatory cascades, and endothelial dysfunction. Conversely, diminished uric acid excretion resulting from CKD further aggravates hyperuricemia, establishing a self-perpetuating vicious cycle. However, epidemiological evidence specific to the pediatric population remains limited, and current clinical management strategies are largely extrapolated from adult studies, lacking evidence-based guidelines tailored to the unique growth and developmental characteristics of children. This review systematically summarizes the epidemiological features, molecular pathogenic mechanisms, clinical implications, and therapeutic approaches for HUA comorbid with pediatric CKD. We specifically highlight uric acid–driven renal injury pathways, the accelerating effect of HUA on CKD progression, and age-specific challenges in pediatric diagnosis and standardized intervention. By integrating recent advances in preclinical and clinical research, this review aims to provide a theoretical foundation for the early screening, timely diagnosis, and individualized standardized management of hyperuricemia in children with CKD.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.